Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro

Publication date: Available online 29 October 2018Source: Research in Veterinary ScienceAuthor(s): Agnieszka Jasiecka-Mikołajczyk, Jerzy J. Jaroszewski, Tomasz MaślankaAbstractOclacitinib (OCL) is a novel immunosuppressive agent approved for dogs that controls itch and inflammation in allergic disease via the inhibition of the JAK/STAT pathway. This paper investigates the in vitro effect of OCL, a novel Janus kinase inhibitor, on selected canine regulatory (Treg) and effector (Teff) CD4+ and CD8+ T cells. Exposure of peripheral blood lymphocytes to OCL did not affect the transcription factor Foxp3 (Forkhead Box P3 protein) expression in CD25+CD4+ and CD25+CD8+ T cells. Moreover, OCL did not influence constitutive CD25 expression on these cells although it reduced the activation-induced C...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EQjDs0